Stay updated on Dolutegravir Plus NRTIs in HIV-2 Clinical Trial

Sign up to get notified when there's something new on the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The displayed site revision updates from v3.8.0 to v3.8.1, with no change to the clinical trial record.
    Difference
    0.1%
    Check dated 2026-11-18T00:49:39.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The clinical trial record for dolutegravir plus two NRTIs in treatment-naïve people with HIV-2 is now displayed, including study design, participation criteria, locations, and outcome measures.
    Difference
    42%
    Check dated 2026-11-10T18:50:41.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T19:07:48.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    A site-wide NIH transition notice appears above the unchanged 403 Forbidden page, and the site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T19:16:21.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The 403 Forbidden page’s footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T20:14:44.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed, replacing the study details with a simple error message and a Home link.
    Difference
    17%
    Check dated 2026-09-22T22:20:34.000Z thumbnail image

Stay in the know with updates to Dolutegravir Plus NRTIs in HIV-2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page.